Fri.Sep 20, 2024

article thumbnail

Magazine: Enhancing therapy adherence with prodrugs

Pharmaceutical Technology

In this issue: Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing vaccines for Disease X, and more.

article thumbnail

Apellis eye drug again turned back in Europe

Bio Pharma Dive

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the company’s operations in Europe.

Drugs 298
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI boom set to revolutionise healthcare in Europe

Pharmaceutical Technology

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

289
289
article thumbnail

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data

Bio Pharma Dive

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Drugs 162
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space 

Pharmaceutical Technology

The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.

264
264
article thumbnail

FTC sues major pharmacy benefit managers over insulin prices

Bio Pharma Dive

The agency brought action against Caremark, Express Scripts and Optum Rx on Friday, and warned that all drug manufacturers “should be on notice” as well.

Insulin 130

More Trending

article thumbnail

Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval

Fierce Pharma

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. With the nod, Dupixent becomes the first biologic treatment for COPD patients in the U.S.

128
128
article thumbnail

Sanofi eyes approval after MS therapy slows disease progression by 31%

Pharmaceutical Technology

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.

130
130
article thumbnail

Bristol Myers Squibb axes 79 more in NJ as $1.5B cost-reduction program rolls on

Fierce Pharma

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program. | Bristol Myers Squibb is laying off an additional 79 staffers in Lawrenceville, New Jersey. The cuts will be effective between Dec. 12 and May 30 of next year and are part of BMS's $1.5 billion cost reduction program.

119
119
article thumbnail

Pharmaceutical packaging companies, materials, and containment services for the pharmaceutical industry

Pharmaceutical Technology

Pharmaceutical Technology has listed the leading pharmaceutical packaging companies and containment solutions suppliers. Download for free.

Packaging 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa

Fierce Pharma

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday.

article thumbnail

Biotechs investigate ways to adapt to new clinical trial regulation and economic flux

Pharmaceutical Technology

The Outsourcing in Clinical Trials New England conference will gather pharma experts to discuss the current clinical trial landscape.

article thumbnail

Astellas brings its first digital health product to US

pharmaphorum

Astellas is ready to launch its first digital health product in the US, called Digitiva, which provides at-home monitoring of people with heart failure

article thumbnail

EMA CHMP recommends label update to Novo Nordisk’s Wegovy

Pharmaceutical Technology

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s Wegovy label.

Medicine 130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

After prior snub, Zevra clinches FDA approval for rare lysosomal storage disorder drug Miplyffa

Fierce Pharma

For Zevra Therapeutics and its rare neurodegenerative disease med arimoclomol, the second time’s the charm. | The FDA approved Zevra’s arimoclomol capsules to treat the rare lysosomal storage disorder Niemann-Pick disease type C in conjunction with Johnson & Johnson’s enzyme inhibitor miglustat. Arimoclomol, which will fly under the brand name Miplyffa, is now the first FDA-approved therapy for NPC.

article thumbnail

NHS England to offer Daiichi Sankyo’s quizartinib for AML

Pharmaceutical Technology

The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).

130
130
article thumbnail

With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine

Fierce Pharma

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17. With the green light, FluMist is now the only flu vaccine in the U.S. patients can give to themselves.

article thumbnail

J&J nets another key approval for blockbuster hope Rybrevant

pharmaphorum

J&J's target of $5bn in sales for Rybrevant has moved a step closer, after an FDA approval for second-line treatment of EGFR+ NSCLC

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Johnson & Johnson tacks on another NSCLC approval in pursuit of AstraZeneca's Tagrisso

Fierce Pharma

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC). | Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC).

111
111
article thumbnail

5 patient travel strategies to impact enrolment diversity in clinical research

pharmaphorum

Discover five effective patient travel strategies to improve diversity in clinical research enrolment. Learn how to enhance inclusivity and representation in your research studies.

article thumbnail

Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius

Fierce Pharma

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been left in the cold once again. | Europe’s Committee for Medicinal Products for Human Use has confirmed its negative stance on pegcetacoplan in geographic atrophy, an advanced form of age-related macular degeneration that can lead to blindness.

Medicine 111
article thumbnail

AI study shows GLP-1s could help prevent heart disease in millions

BioPharma Reporter

Dandelion Health used its new clinical AI marketplace to analyze real-world data, showing that GLP-1 drugs may help prevent cardiovascular disease (CVD) for a seven times larger population than previously researched.

Drugs 64
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations

Fierce Pharma

Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations aliu Fri, 09/20/2024 - 09:21

article thumbnail

Unleashing the Power of AI: Predictive Analytics in Healthcare Marketing

Intouch Solutions

Predictive analytics is revolutionizing healthcare marketing by leveraging AI to make data-driven decisions. In this POV, we explore how the use of predictive models enhances engagement by targeting the right audiences, optimizing marketing strategies and best utilizing marketing dollars. We showcase real-world applications where AI-powered predictive analytics has led to significant increases in marketing effectiveness and patient care.

article thumbnail

Job losses loom at Achilles as TIL therapy platform is cut

pharmaphorum

Job losses loom at Achilles as TIL therapy platform is cut Phil.

59
article thumbnail

Streamlining Pharmacy Purchasing and Procurement

Pharmaceutical Commerce

In an interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, discusses why mitigating the impact of rising costs is imperative, while explaining the benefit of advanced analytics tools.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Simplifying ePRO Data Collection: The Benefits of BYOD with TrialKit

Crucial Data Soutions

The Challenge of Device Provisioning in Clinical Trials In clinical trials, gathering timely and accurate data from patients is essential. The post Simplifying ePRO Data Collection: The Benefits of BYOD with TrialKit appeared first on Crucial Data Solutions.

article thumbnail

Who Role Do Vertical Relationships Play When It Comes to Quality of Care?

Pharmaceutical Commerce

A study examines if this PCP-large health system dynamic impacts patient outcomes.

52
article thumbnail

Best Practices for Successfully Transitioning a Patient Services Hub

Drug Channels

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health Josh discusses challenges manufacturers may face when outsourcing patient support programs. He outlines a process that smoothly transitions hubs and minimizes disruptions for patients and healthcare providers. To learn more, download the 3-step guide to patient hub transitions.

article thumbnail

The Challenges and Promise of CAR T-Cell Therapy in Oncology

XTalks

Chimeric antigen receptor T-cell therapy (CAR T) has provided substantial benefit to patients with certain hematological malignancies and has significant opportunity for growth. As of 2024, the global CAR T-cell therapy market is valued at $4.6 billion and is projected to reach $15.2 billion by 2035. Despite this, CAR T-cell therapies are currently limited to treating B-cell malignancies, and most patients do not achieve progression-free survival.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.